APA (7th ed.) Citation

Iacoboni, G., Rejeski, K., Villacampa, G., van Doesum, J. A., Chiappella, A., Bonifazi, F., . . . Barba, P. (2022). Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 6(12), 3606-3610. https://doi.org/10.1182/bloodadvances.2021006922

Chicago Style (17th ed.) Citation

Iacoboni, Gloria, et al. "Real-world Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma." Blood Advances 6, no. 12 (2022): 3606-3610. https://doi.org/10.1182/bloodadvances.2021006922.

MLA (9th ed.) Citation

Iacoboni, Gloria, et al. "Real-world Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma." Blood Advances, vol. 6, no. 12, 2022, pp. 3606-3610, https://doi.org/10.1182/bloodadvances.2021006922.